XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
December 24, 2025 16:00 ET | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN,…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Darkiris Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Hong Kong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- DarkIris Inc. (Nasdaq: DKI)…
Biotic innovation tackles iron deficiency in women – now recognized across three continents
STOCKHOLM, Sept. 22, 2025 /PRNewswire/ -- A health solution designed to improve…
